Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus

Donald B. Wiest, Julianne B. Pinson, Peter S. Gal, Richard Brundage, S. Schall, J. Laurence Ransom, Richard L. Weaver, Dilip Purohit, Y. Brown

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

The population pharmacokinetics of intravenous indomethacin were investigated with 665 indomethacin serum concentrations from 83 neonates (mean t SD: gestational age, 28.8 ± 2.5 weeks; postnatal age, 5.7 ± 4.7 days; birth weight, 1.13 ± 0.40 kg) receiving indomethacin for symptomatic patent ductus arteriosus. A one-compartment open model was used for pharmacokinetic analysis. Hypotheses were tested to determine which developmental and demographic data influenced clearance (CL) and volume of distribution (Varea). In the final regression equation CL and V. were modeled as a function of body weight and postnatal age (PNA) from 0 to 20 days. Final estimates were as follows: CL (ml/hr) = 2.63 · weight (kg) + 0.244 · PNA (days) and Varea, (L) = 0.28 · weight (kg) + 0.0041 · PNA (days). The coefficients of variation for interindividual variability in CL and Varea were 77% and 28%, respectively. Intraindividual variability was 19%. These mean population parameter estimates should prove useful in designing dosage regimens to achieve desired indomethacin concentrations for neonates from 0 to 20 days of age with symptomatic patent ductus arteriosus.

Original languageEnglish (US)
Pages (from-to)550-557
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume49
Issue number5
DOIs
StatePublished - May 1991

Fingerprint Dive into the research topics of 'Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus'. Together they form a unique fingerprint.

Cite this